Amgen (NASDAQ:AMGN) executives said the company delivered a “strong first quarter” and remains positioned to meet its goals ...
By Deena Beasley April 30 (Reuters) - Amgen on Thursday said its first-quarter product sales rose 4%, helped by demand for ...
Amgen has pulled the plug on midstage drug candidates for cancer and the autoimmune disease Sjögren’s syndrome, terminating ...
The FDA’s real-time clinical trial mechanism allows drug sponsors to transmit data immediately to the regulator through the ...
Amgen Inc. reported better-than-expected first-quarter results even as some newer drugs that analysts expect to drive growth ...
Earlier this year, when the FDA asked Amgen to pull its rare disease drug Tavneos from the market, the California drugmaker ...
Amgen Inc () has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful investing tools for smar ...
The FDA has renewed calls for Amgen’s Tavneos to be pulled from the market, saying it has discovered new evidence that study ...
Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its ...
Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.
Amgen Inc (AMGN) reports a robust 4% growth in product sales, driven by key growth drivers, while navigating patent expirations and increased competition.
A former Amgen Inc. employee filed a proposed class action challenging the biotechnology company’s practice of charging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results